BPC-157 (Body Protection Compound-157): A Practical Guide

Overview

BPC-157 is a synthetic pentadecapeptide (15 amino acids; sequence: GEPPPGKPADDAGLV) derived from a naturally occurring partial sequence found in human gastric juice. It was isolated and characterized by Predrag Sikirić and colleagues at the University of Zagreb beginning in the late 1980s, and has been studied extensively in animal models as a tissue repair and cytoprotective agent. BPC-157 is sometimes called "body protection compound" reflecting its broad range of protective and healing effects in preclinical studies. It is not FDA-approved for any indication and has no completed large-scale human clinical trials as of 2026; its use in humans is exclusively off-label and compounded. Despite the absence of human RCT data, BPC-157 has become one of the most widely discussed and used peptides in functional medicine, sports medicine, and longevity communities due to its extraordinarily consistent and potent healing effects across dozens of animal studies encompassing GI, tendon, ligament, bone, muscle, nerve, cardiovascular, and CNS tissues.

Mechanism of Action

BPC-157 exerts effects through multiple interconnected pathways:

VEGF and angiogenesis: BPC-157 strongly upregulates vascular endothelial growth factor (VEGF) and its receptor (VEGFR2), promoting angiogenesis at injury sites — accelerating vascular network formation and nutrient delivery to healing tissue.

Nitric oxide (NO) pathway: BPC-157 activates eNOS (endothelial nitric oxide synthase) via the FAK/paxillin pathway, increasing local NO production. NO promotes vasodilation, cellular migration, and collagen remodeling.

Tendon and ligament fibroblast stimulation: In tendon healing models, BPC-157 dramatically accelerates fibroblast proliferation, migration, and collagen synthesis. Expression of tendon growth factor (EGF, PDGF) receptors is upregulated, and matrix metalloproteinase activity is modulated to favor constructive rather than destructive collagen remodeling.

GI mucosal cytoprotection: BPC-157 maintains prostaglandin synthesis and modulates COX-2 activity to protect gastric mucosa. It accelerates ulcer healing via both PGE2-dependent and PGE2-independent mechanisms. It also reduces the mucosal damage caused by NSAIDs, alcohol, and chemotherapeutic agents — a property discovered in the original gastric juice context.

Dopamine and serotonin system modulation: BPC-157 uniquely modulates both dopaminergic and serotonergic systems in the brain — increasing dopamine synthesis, preventing dopamine depletion, and modulating 5-HT receptor function. This has produced antidepressant and anxiolytic effects in multiple animal models.

NF-κB suppression: BPC-157 reduces pro-inflammatory NF-κB signaling in injured tissue while maintaining the inflammatory signals needed for tissue repair — a modulating rather than suppressive effect on inflammation.

Skeletal muscle (MAPK/ERK): In muscle injury models, BPC-157 activates MEK/ERK and Akt pathways to promote myotubeformation, satellite cell proliferation, and muscle regeneration.

Evidence Base

Animal model breadth: BPC-157 has demonstrated healing effects in animal models for: gastric ulcers, colitis, IBS, esophageal damage, tendon injuries (Achilles tendon transection), ligament injuries (MCL), bone fractures, muscle injuries, spinal cord injuries, corneal damage, fistulas, anastomoses, NSAID-induced liver and kidney damage, traumatic brain injury, peripheral nerve damage, and heart arrhythmias. The consistency and potency across such diverse tissue types is unusual in animal pharmacology and is a primary reason for significant clinical interest.

GI evidence: The strongest and most replicated animal evidence relates to gastroprotection and GI healing. BPC-157 heals gastric ulcers at lower doses and faster than omeprazole in comparative rat studies. It prevents NSAID-induced gastric damage and accelerates anastomosis healing post-surgery — relevant to GI surgical settings.

Tendon/musculoskeletal: Multiple published studies show significantly faster Achilles tendon healing with BPC-157 vs controls, with superior tensile strength recovery. This has driven its adoption in sports medicine peptide protocols.

Human evidence: five published human studies exist, covering roughly 80 subjects in total — 24 healthy volunteers (rectal enema), approximately 26 patients with ulcerative colitis, 17 patients with knee pain (intra-articular, given as a compounded combination with thymosin beta-4), 12 patients with interstitial cystitis, and 2 healthy volunteers (intravenous). One of these is a randomized, double-blind, placebo-controlled trial: 53 subjects with ulcerative colitis given an 80 mg enema daily for two weeks. Mean change in disease activity index was −3.2 (95% CI −5.58 to −0.82) on BPC-157 versus −1.6 (95% CI −3.86 to 0.67) on placebo, with an estimated between-group difference of 1.6 (95% CI −4.84 to 1.62); the interval crosses zero. It was published as a meeting abstract only. A phase 1 oral safety and pharmacokinetic trial (NCT02637284, 42 healthy subjects, Tijuana, October 2015 to March 2016) has never posted results and remains listed as status unknown.

Route of administration: no published human study has administered BPC-157 by the oral, subcutaneous, nasal, or transdermal route — the four routes in general use. Human exposure to date has been rectal, intra-articular, intravesical, and intravenous.

Limitations: the great majority of mechanistic and efficacy data comes from the Sikirić group at the University of Zagreb, and the output has continued at pace — 2025 and 2026 alone added rodent work on adrenalectomy and vascular recovery, aortic wall remodelling assessed by infrared spectroscopy, corneal ulcer healing, and a review positioning the peptide as a bidirectional regulator of haemorrhage and thrombosis. The volume is real; the independent replication is not. Most rodent studies use intraperitoneal or intragastric administration, which does not translate cleanly to subcutaneous dosing in humans.

Dosing & Timing

All human dosing is off-label and extrapolated from animal studies.

Route note: the two routes in the table below — oral capsule and subcutaneous injection — are the two routes for which no published human study exists. Circulating doses are extrapolated from rodent work in which administration was predominantly intraperitoneal or intragastric.

Oral vs injection for GI: Oral BPC-157 is stable in gastric acid (originally identified in gastric juice); oral administration is preferred for GI-targeted effects. SQ injection produces systemic distribution.

Cycle length: 4–12 week cycles are most commonly used; longer cycles (6+ months) reported by some practitioners for chronic conditions. No established maximum safe duration in humans.

Forms & Bioavailability

BPC-157 is available as: - Lyophilized powder for reconstitution (most common; used for SQ injection) - Oral capsules (compounded; stability and bioavailability data limited but growing) - Nasal spray (experimental; used for CNS targeting in some protocols)

Quality control is the primary concern when sourcing from compounding pharmacies. BPC-157 should be reconstituted with bacteriostatic water and stored at 4°C; stable for 4 weeks after reconstitution.

Regulatory status — United States: BPC-157 is not an approved drug and no approved product contains it. Its compounding status has moved twice in the past year. The FDA placed it in Category 2 — the “significant safety risks” category — in September 2023, which in practice barred compounding pharmacies from preparing it. The FDA removed it from Category 2 on 22 April 2026. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 (free base and acetate) to the Section 503A bulk drug substances list, voting against the recommendation of the FDA’s own review staff. That recommendation is advisory; adding a substance to the 503A list requires rulemaking, which has not yet issued. The practical position today: the prohibition is gone, the agency’s advisers have endorsed affirmative listing, and the listing itself is pending. It remains not a legal dietary ingredient, and sale as a supplement or over-the-counter drug in the United States is not permitted.

Regulatory status — outside the United States: no medicines regulator anywhere has approved a BPC-157 product — not the European Medicines Agency, the United Kingdom Medicines and Healthcare products Regulatory Agency, Health Canada, Japan’s Pharmaceuticals and Medical Devices Agency, or Australia’s Therapeutic Goods Administration. Australia has moved in the opposite direction to the United States: BPC-157 is a Schedule 4 (prescription only) substance listed in Appendix D, clause 5 of the Poisons Standard, given legal effect in the Therapeutic Goods (Poisons Standard — June 2024) Instrument 2024 with a commencement date of 1 June 2024. For context, the peptide has been under investigation in Croatia, its country of origin, for roughly three decades without ever obtaining a Croatian or European marketing authorisation. Verify current legal status in your jurisdiction before prescribing or obtaining.

Sport: BPC-157 is prohibited at all times under the World Anti-Doping Agency Prohibited List, category S0 (non-approved substances), on the basis that it is not approved for human clinical use by any global regulatory authority. A therapeutic use exemption is not realistically obtainable for a substance with no approved indication.

Product quality: there is no United States, European, Japanese, or International Pharmacopeia monograph for BPC-157. Certificates of analysis submitted to the FDA in the nomination packages reported purity figures only (97.8% and 98.34%), with no results for specified impurities, aggregates, bioburden, or bacterial endotoxin. Material sold as “research use only” carries no meaningful quality assurance.

Safety & Side Effects

Animal safety studies: 28-day repeat-dose intramuscular toxicity work in rats and dogs produced findings the FDA characterised as clinically relevant safety signals — shortening of the activated partial thromboplastin time in rats, prolongation in dogs, together with liver-associated changes (alanine aminotransferase, glucose, triglycerides). Genotoxicity assays (Ames, chromosome aberration, micronucleus) were negative. No carcinogenicity study of BPC-157 has been published; that is an absence of data, not a negative result.

Human reports (observational): Most commonly reported: mild nausea at initiation, injection site discomfort, transient dizziness. No serious adverse events consistently reported in the functional medicine community literature.

Theoretical concerns: - VEGF upregulation: if used in individuals with active or occult malignancy, VEGF-driven angiogenesis could theoretically promote tumor vascularization - No long-term human safety data

Contraindicated (theoretical): Active cancer; pregnancy (no safety data).

Drug & Supplement Interactions

Who Should Consider It

• Athletes with tendon, ligament, or muscle injuries seeking accelerated tissue healing
• Individuals with inflammatory bowel disease, gastric ulcers, or GI permeability issues
• Post-surgical patients seeking to accelerate tissue healing (GI anastomosis)
• Those with NSAID-induced GI damage
• Individuals with mood dysregulation interested in dopaminergic/serotonergic mechanisms

Bottom Line

BPC-157 is one of the most impressive preclinical healing agents, but it lacks independent replication and human efficacy data, and its regulatory position is in flux: the FDA lifted its Category 2 restriction in April 2026 and its advisory committee has since recommended adding it to the 503A compounding list, though that listing has not yet issued and it remains unapproved as a drug and not a legal dietary ingredient. Any use should be framed as experimental, with careful informed consent, oncologic caution (VEGF-driven angiogenesis risk in active malignancy), and full regulatory awareness. The single randomized human trial did not separate from placebo, and no published human study has used the oral or subcutaneous route — that does not invalidate the animal data, but it does mean the field still awaits the translational confirmation the compound deserves.

Last reviewed: 2026.